Results 111 to 120 of about 10,523 (190)

Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation. [PDF]

J Am Heart Assoc, 2023
LaFratte C, Peasah SK, Huang Y, Hall D, Patel U, Good CB.   +5 more
europepmc   +1 more source

Impact of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor on Immune-Inflammatory Responses in the Acute Phase of Ischemic Stroke. [PDF]

J Inflamm Res
Li Z, Sun C, Zhang Q, Ji L, Zhang Y, Li S, Gu M, Gao J, Huang Z, Wang M, Zhou J, Zhu L, Jiang T, Zhou Q, Deng Q.   +14 more
europepmc   +1 more source

Determinants of circulating PCSK9 levels and the efficacy of PCSK9 inhibitor therapies in chronic kidney disease: a systematic review. [PDF]

Eur J Clin Pharmacol
Ábel T, Benczúr B, Csajbókné ÉC.
europepmc   +1 more source

Synthesis of a PCSK9 Inhibitor [PDF]

Synfacts, 2018
openaire   +1 more source

Methodological Challenges of Emulating a Target Trial to Assess Effectiveness of Timing of PCSK9 Inhibitor Treatment Initiation Post Myocardial Infarction. [PDF]

Pharmacoepidemiol Drug Saf
Cars T, Gustafsson S, Chan Q, Dhalwani N, Kent ST, Briggs A, Gale CP, Gitt A, Jukema JW, Steg PG, Sundström J, James S, Hagström E, Brookhart MA.   +13 more
europepmc   +1 more source

Access to PCSK9 Inhibitors

Reviews in Cardiovascular Medicine, 2018
Jennifer G. Robinson, Norman E. Lepor, Seth J. Baum   +2 more
openaire   +1 more source

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients. [PDF]

Circulation
Vega RB, O'Mahony G, Barbour AM, Yu H, Knöchel J, Brengdahl J, Hochdörfer T, Bergenholm L, Töppner Carlsson E, Ahnmark A, Underwood CR, Rudvik A, Carter D, Laru J, Gutgsell A, Twaddle L, Garkaviy P, Bogstedt A, Hurt-Camejo E, Miliotis T, Ryaboshapkina M, Hober A, Hubbard B, Serrano-Wu M, Kaushik V, Geschwindner S, McCarthy MC, Lindén D, Rosenmeier JB.   +28 more
europepmc   +1 more source

Impact of CYP2C19 Genotype Variants on PCSK9 Inhibitor Efficacy in Lipid-Lowering Among Patients With Symptomatic Intracranial Atherosclerotic Stenosis. [PDF]

Lipids
Zhao C, Wang N, Shi D, Zhou H, Chen D, Chen G.   +5 more
europepmc   +1 more source

Outcomes of PCSK9 Inhibitors

JACC: Advances, 2023
openaire   +1 more source

PCSK9 inhibitor failure in a statin-intolerant FH patient with a novel LDLR variant: a case report. [PDF]

Front Cardiovasc Med
Li Y, Jiang H, Xiong Y, Yan S, Chen X.
europepmc   +1 more source